Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Oxford BioMedica ( (GB:OXB) ) just unveiled an update.
Oxford BioMedica has reiterated its full-year guidance for 2025, supported by strong demand and commercial momentum. The company’s ‘One OXB’ strategy has led to a significant financial performance, with a 78% organic revenue growth and a doubled order book, indicating a robust demand for its CDMO services. In 2024, the company expects revenues of £127-129 million, reflecting a 42-44% increase over 2023. The UK site achieved profitability at the operating EBITDA level in the second half of 2024, while the France and US sites are showing narrowing losses. The strong balance sheet and increased commercial momentum suggest continued progress and profitability in 2025.
More about Oxford BioMedica
OXB (LSE: OXB) is a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy. With 30 years of experience, OXB provides viral vector development and manufacturing expertise for lentivirus, adeno-associated virus (AAV), and other viral vectors, collaborating with leading pharmaceutical and biotechnology companies.
YTD Price Performance: -4.74%
Average Trading Volume: 5,733
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $520.2M
For a thorough assessment of OXB stock, go to TipRanks’ Stock Analysis page.
